Filing Analysis
Akari Therapeutics (AKTX) entered into a Securities Purchase Agreement on May 20, 2026 for a private placement offering of approximately $5.5 million gross proceeds. The offering involves 1,470,588 ADSs (or pre-funded warrants in lieu) at $3.74 per unit, accompanied by three series of warrants (Series H, I, and J), with funding structured across three tranches closing between May 27 and July 15, 2026. The placement agent (Paulson Investment Company) receives both a 2% cash fee and 117,647 ADSs (8% of total ADSs issued), and shareholder approval is required for warrant issuance.
🚩 Red Flags
- Small raise of only ~$5.5M gross ($5.375M net) signals limited financial runway and potential cash burn concern for a clinical-stage biotech
- Highly dilutive structure: each ADS unit carries THREE warrant series (H, I, J), each exercisable for one additional ADS — potential 4x dilution per unit if all warrants exercised
- Placement agent compensation is unusually high: 2% cash fee PLUS 8% of total ADSs issued (117,647 ADSs), effectively a dual-compensation structure
- Shareholder Approval is a contingent condition for warrant and placement agent ADS issuance — creates execution risk and potential deal uncertainty
- Use of proceeds for 'working capital and general corporate purposes' suggests no specific operational milestone, indicating ongoing cash need
- Offering price of $3.74/ADS may reflect significant discount to market, implying dilution to existing shareholders
- Three-tranche funding structure (not a single close) introduces future closing risk if market conditions deteriorate
- Multiple 8-K items filed simultaneously (Items 1.01, 3.02, 9.01)
📋 Key Facts
- Securities Purchase Agreement dated May 20, 2026 for a private placement offering
- 1,470,588 ADSs (each representing 80,000 ordinary shares) offered at $3.74 per Unit (ADS Unit Purchase Price)
- Pre-Funded Warrants offered at $3.739 per Unit (ADS Unit Purchase Price minus $0.001 exercise price)
- Gross proceeds expected to be approximately $5.5 million before deducting ~$125,000 in placement agent fees
- Three warrant series issued per unit: Series H, Series I, and Series J, each exercisable for one ADS at $3.74
- Funding structured in three tranches: ~May 27, 2026 (First Closing), June 15, 2026 (Second Closing), July 15, 2026 (Third Closing)
- Placement Agent (Paulson Investment Company, LLC) receives 2% cash fee AND 117,647 ADSs (8% of total ADSs issued)
- Shareholder Approval required before Series Warrants and Placement Agent ADSs can be issued
- Company must file Form S-3 (or S-1) registration statement within 30 days of Third Closing Date (July 15, 2026)
- Proceeds to be used for working capital and general corporate purposes
- Securities sold under Section 4(a)(2) exemption and Rule 506 of Regulation D to accredited investors only
- Filing signed by Abizer Gaslightwala, President and CEO, on May 22, 2026
Akari Therapeutics announced a 1-for-40 reverse split of its American Depositary Shares (ADSs) by changing the ratio from 1:2,000 to 1:80,000 ordinary shares. The change is scheduled to take effect on March 31, 2026, in an effort to regain or maintain compliance with Nasdaq's minimum bid price requirement.
🚩 Red Flags
- Significant 1-for-40 reverse split ratio.
- Explicit mention of uncertainty regarding the ability to satisfy Nasdaq minimum bid price requirements even after the split.
📋 Key Facts
- The ADS ratio will change from one ADS representing 2,000 ordinary shares to one ADS representing 80,000 ordinary shares.
- The action results in a 1-for-40 reverse split of issued and outstanding ADSs.
- The effective date for the ratio change is approximately March 31, 2026.
- The change has no effect on the underlying ordinary shares, only the ADSs.
Akari Therapeutics held a Special General Meeting on March 2, 2026, where shareholders approved the exercisability of a massive volume of warrants issued in late 2025 and early 2026. These approvals, required by Nasdaq Listing Rule 5635, facilitate the potential issuance of over 26 million American Depositary Shares (ADSs) through Series G, Pre-Funded, and Note Exchange warrants.
🚩 Red Flags
- Extreme potential dilution: The warrants approved for exercise represent a significant percentage of the company's total equity (potentially exceeding 50% of current ADS equivalents).
- Reliance on Note Exchange Warrants suggests the company is converting debt to equity to manage its balance sheet.
- The use of Pre-Funded Warrants and Series G Warrants often indicates high-cost capital raising typical of distressed micro-cap entities.
📋 Key Facts
- Shareholders approved the exercisability of Series G Warrants for 10,043,774 ADSs and Placement Agent Warrants for 504,300 ADSs.
- Approved exercisability of Pre-Funded and Series G Warrants for approximately 5.1 million ADSs related to a December 2025 private placement.
- Approved exercisability of Pre-Funded and Note Exchange Warrants for approximately 28.3 million ADSs related to a December 2025 note exchange.
- Total ordinary shares entitled to vote at the meeting was 91,567,009,533 (equivalent to approximately 45.7 million ADSs).
- All resolutions passed with significant majorities, clearing the path for substantial equity dilution.